ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1672
0,56%
Bitcoin
69.305,20
0,06%
Brent Oil
81,965
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Indaptus Therapeutics Inc (INDP)

  7. Indaptus Therapeutics Inc (INDP) Notícias

INDP

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:INDP
DataHoraFonteTítuloCódigoCompanhia
22/05/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
22/05/202409:00GlobeNewswire Inc.Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsNASDAQ:INDPIndaptus Therapeutics Inc
08/05/202409:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
08/05/202409:00GlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
11/04/202408:30GlobeNewswire Inc.Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
28/03/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
25/03/202409:30GlobeNewswire Inc.Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
18/03/202409:00GlobeNewswire Inc.Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024NASDAQ:INDPIndaptus Therapeutics Inc
13/03/202408:30GlobeNewswire Inc.Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
04/03/202409:30GlobeNewswire Inc.Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortNASDAQ:INDPIndaptus Therapeutics Inc
15/02/202410:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
08/02/202410:00GlobeNewswire Inc.Indaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsNASDAQ:INDPIndaptus Therapeutics Inc
23/01/202418:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
04/01/202410:00GlobeNewswire Inc.European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202318:01GlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202310:00GlobeNewswire Inc.Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNASDAQ:INDPIndaptus Therapeutics Inc
31/10/202310:01GlobeNewswire Inc.Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy MeetingNASDAQ:INDPIndaptus Therapeutics Inc
27/09/202309:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the LD Micro Main Event XVINASDAQ:INDPIndaptus Therapeutics Inc
26/09/202309:00GlobeNewswire Inc.Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023NASDAQ:INDPIndaptus Therapeutics Inc
19/09/202309:00GlobeNewswire Inc.Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
06/09/202309:05GlobeNewswire Inc.Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
14/08/202309:00GlobeNewswire Inc.Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
10/08/202309:45GlobeNewswire Inc.Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
07/08/202309:00GlobeNewswire Inc.Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical OfficerNASDAQ:INDPIndaptus Therapeutics Inc
15/06/202309:00GlobeNewswire Inc.Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
31/05/202309:30GlobeNewswire Inc.Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023NASDAQ:INDPIndaptus Therapeutics Inc
30/05/202317:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INDPIndaptus Therapeutics Inc
25/05/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INDPIndaptus Therapeutics Inc
11/05/202308:00GlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
09/05/202309:00GlobeNewswire Inc.Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy PlatformNASDAQ:INDPIndaptus Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:INDP

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
IBOV
Índice Bovespa
BOV
POSI3
POSITIVO TEC ON
BOV
COGN3
COGNA ON
BOV
PDTC3
Padtec ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados